Product Program year 2022 Source: CMS Open Payments

General - Vascular Access

Device Scope

General payments

$25,427

5 payments

Research payments

0 payments

Through program year 2022, $25,427 in general payments and $0 in research payments were reported against General - Vascular Access (Scope).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row

Year	Kind	Amount	Payments
2022	General	$25,427	5

Breakdown

Who paid General payments · program year 2022

Boston Scientific Corporation $25,427 5 payments

Top recipients General payments · program year 2022

Meagan Dunne Urology · Towson, MD $17,200 68% · 1 payment
Philip Zhao Urology · New York, NY $8,000 31% · 1 payment
Kara Choate Urology · Irving, TX $112 <1% · 1 payment
Michael Glass Parker, CO $103 <1% · 1 payment
Bryan Hoff Urology · Bloomington, IN $12 <1% · 1 payment

Each share is of general payments naming this product in 2022.

Specialties paid General payments · program year 2022

Urology $25,325 100% · 4 practitioners

Each share is of general payments naming this product to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2022

Maryland $17,200 68% · 1 recipient
New York $8,000 31% · 1 recipient
Colorado $215 <1% · 2 recipients
Indiana $12 <1% · 1 recipient

Each share is of general payments naming this product in 2022 where a state was reported.

Records

5 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.